JUST Medical
Chinese orthopedic medical device company specializing in 3D-printed hip and knee implants, surgical robots, and regenerative biomaterials for joint disease treatment.
- CEO / Founder
- Liu Nian (刘念)
- Team Size
- 501-1000
- Stage
- Growth Stage
- Total Funding
- $52M
- Latest Round
- Series B
- Key Investors
- Qiming Venture Partners; SDIC Unity Capital (国投创合); YuanSheng Venture Capital (元生创投); Jifeng Capital (济峰资本); Tasly Capital (天士力资本); Shengde Yuekai (晟德悦凯); Fangyuan Capital (方圆资本)
Technology & Products
Key Products
3D SEE® Trabecular Hip Prosthesis System (3D-printed EBM titanium alloy); SKII PS/PS+/CR/RPS Total Knee Systems; RSK Revision Knee System; HRSK Rotating Hinge Knee; AUSK Unicompartmental Knee; EPS TKA Surgical Robotic System; Mysmond Oxidized Zirconium-Niobium Femoral Head; Artidyz Bioceramic Bone Graft; Cartistem® SVF Adipose Collector; 3D-customized revision implants
Technological Advantage
EBM 3D metal printing for trabecular bone-mimicking structures (600-800μm pores, 75-80% porosity); NMPA Class III medical device certifications for 3D-printed implants; AI surgical robot platform; vertically integrated from R&D to manufacturing to sales; 5 R&D centers across China and US
Differentiation
Value Proposition
Provides comprehensive joint disease treatment solutions with 3D-printed orthopedic implants (hip/knee), surgical robots, and regenerative biomaterials.
How They Differentiate
Combines 3D-printed metal implants (EBM technology), AI-powered surgical robots (EPS TKA system), and regenerative medicine (SVF adipose processing, bioceramic bone grafts). Has 5 R&D centers across Tianjin, Beijing, Shanghai, and the US, plus a dedicated 3D JCT medical-industrial interaction center.
Market & Competition
Target Customers
Hospitals, orthopedic surgeons, medical device distributors, healthcare institutions performing joint replacement surgeries
Industry Verticals
Orthopedic surgery; Joint replacement (hip, knee, shoulder); Sports medicine; Regenerative medicine
Competitors
AK Medical (爱康医疗, 1789.HK); Chunli Medical (春立医疗, 688236.SH); B. Braun / Aesculap
Growth & Milestones
Growth Metrics
3 consecutive years of >50% CAGR in product sales (as of 2021); 650,000+ implantations worldwide; sales in 49+ countries
Major Milestones
1958: Company origins (predecessor); 2004: Company formally established; 2019-07: NMPA approval for 3D-printed trabecular hip prosthesis (China's 2nd 3D-printed orthopedic implant approval); 2019-08: Series A funding ($15M); 2021-05: Series B funding ($34M); 2021-06: Smart manufacturing factory Phase I launch; 2025: 54 global Class III medical device registrations, 286+ global patents, 650,000+ implantations worldwide
Notable Customers
650,000+ implantations worldwide; sales network covering all Chinese provinces and 49+ countries